Tvarůžková Z, Pavlová Š, Doubek M, Mayer J, Pospíšilová Š. Lymphoproliferative disease in patients with autoimmune and inflammatory diseases: significance of antigenic stimulation and inflammatory processes
Authors:
Zuzana Tvarůžková; Šárka Pavlová; Michael Doubek; Jiří Mayer; Šárka Pospíšilová
Authors place of work:
Masarykova univerzita v Brně, Lékařská fakulta, Interní hematoonkologická klinika FN Brno, Centrum molekulární biologie a genové terapie
Published in the journal:
Čas. Lék. čes. 2011; 150: 161-168
Category:
Review Article
Summary
Evidence has been growing that the pathogenesis of lymphoproliferative disease involves immune processes deregulation. It is believed that antigens or immunological elements can trigger transformation of normal lymphocyte polyclonal population into monoclonal neoplastic disorder – lymphoproliferative disease. Extensive studies point to the link between malignant lymphoma development and autoimmune or inflammatory diseases – namely rheumatoid arthritis, Sjörgen’s syndrome, coeliac disease, systemic lupus erythematosus or thyroiditis. Increased risk of lymphoproliferative disease development was also proved for some infections. These infections involve both viral (e.g. Epstein-Barr virus, HIV or hepatitis C virus) and bacterial agents (e.g. Helicobacter pylori, Borrelia burgdorferi). Besides various lymphomas, the links to autoimmune/inflammatory diseases have also been described in chronic lymphocytic leukaemia. Regarding clinical medicine, it is necessary to distinguish patients with autoimmune, inflammatory and infectious diseases who are at the increased risk of tumour development. New approaches must be found to lower this risk. Also, the relationship between autoimmune/inflammatory disease therapy and lymphoma development should be clarified. Although lymphomas associated with autoimmune and inflammatory diseases represent only a small proportion of all lymphomas, any new findings regarding these diseases can cast light on lymphoma pathogenesis as a whole.
Key words:
lymphoma, leukaemia lymphocytic chronic B-cell, antigens, autoimmune diseases, inflammation, lymphocyte activation, cell transformation neoplastic.
Zdroje
1. Smedby K, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006; 15: 2069–2077.
2. Smedby K, Askling J, Mariette X, et al. Autoimmune and inflammatory disorders and risk of malignant lymphomas – an update. J Intern Med 2008; 264: 514–527.
3. Smedby K, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006; 98: 51–60.
4. Ekström Smedby K, Vajdic C, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111: 4029–4038.
5. Goldin L, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer 2009; 124: 1497–1502.
6. Anderson L, Gadalla S, Morton L, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009; 125: 398–405.
7. Yamamoto K. Pathogenesis of Sjögren‘s syndrome. Autoimmun Rev 2003; 2: 13–18.
8. BjörnĆdal L, Löfström B, Yin L, et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 2002; 31: 66–71.
9. Prokopová L. Celiakie – co má vědět ambulantní internista. Interní Med 2008; 10: 7.
10. Askling J, Linet M, Gridley G, et al. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology 2002; 123: 1428–1435.
11. Isaacson P. Gastrointestinal lymphoma. Hum Pathol 1994; 25: 1020–1029.
12. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203–208.
13. Holmes G, Prior P, Lane M, et al. Malignancy in coeliac disease – effect of a gluten free diet. Gut 1989; 30: 333–338.
14. Bagdi E, Diss T, Munson P, et al. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood 1999; 94: 260–264.
15. Zintzaras E, Voulgarelis M, Moutsopoulos H. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337–2344.
16. Gridley G, Klippel J, Hoover R, et al. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994; 120: 35–39.
17. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3‑year prospective study in France. Blood 2002; 99: 3909–3915.
18. Baecklund E, Sundström C, Ekbom A, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003; 48: 1543–1550.
19. Holm L, Blomgren H, Löwhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985; 312: 601–604.
20. Derringer G, Thompson L, Frommelt R, et al. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol 2000; 24: 623–639.
21. Troch M, Woehrer S, Streubel B, et al. Chronic autoimmune thyroiditis (Hashimoto‘s thyroiditis) in patients with MALT lymphoma. Ann Oncol 2008; 19: 1336–1339.
22. Sigurgeirsson B, Lindelöf B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326: 363–367.
23. Hill C, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96–100.
24. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005; 54: 617–622.
25. Gelfand J, Shin D, Neimann A, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006; 126: 2194–2201.
26. Nielsen N, Rostgaard K, Rasmussen S, et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 2006; 118: 979–984.
27. Askling J, Klareskog L, Blomqvist P, et al. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006; 65: 1184–1187.
28. Faurschou M, Sorensen I, Mellemkjaer L, et al. Malignancies in Wegener‘s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008; 35: 100–105.
29. Zendehdel K, Nyrén O, Ostenson C, et al. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003; 95: 1797–1800.
30. Hagler K, Lynch JJ. Paraneoplastic manifestations of lymphoma. Clin Lymphoma 2004; 5: 29–36.
31. Sallah S, Sigounas G, Vos P, et al. Autoimmune hemolytic anemia in patients with non-Hodgkin‘s lymphoma: characteristics and significance. Ann Oncol 2000; 11: 1571–1577.
32. Hegde U, Wilson W, White T, et al. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002; 100: 2260–2262.
33. Borthakur G, O‘Brien S, Wierda W, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors. Br J Haematol 2007; 136: 800–805.
34. Fisher S, Fisher R. The epidemiology of non-Hodgkin‘s lymphoma. Oncogene 2004; 23: 6524–6534.
35. Fisher S, Fisher R. The emerging concept of antigen-driven lymphomas: epidemiology and treatment implications. Curr Opin Oncol 2006; 18: 417–424.
36. Libra M, Gasparotto D, Gloghini A, et al. Hepatitis C virus (HCV) I hepatitis C virus (HCV) infection and lymphoproliferative disorders. Front Biosci 2005; 10: 2460–2471.
37. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–789.
38. Goodlad J, Davidson M, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol 2000; 24: 1279–1285.
39. Ferreri A, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004; 96: 586–594.
40. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350: 239–248.
41. Shah K, Young L. Epstein-Barr virus and carcinogenesis: beyond Burkitt‘s lymphoma. Clin Microbiol Infect 2009; 15: 982–988.
42. Tao Q, Robertson K, Manns A, et al. Epstein-Barr virus (EBV) in endemic Burkitt‘s lymphoma: molecular analysis of primary tumor tissue. Blood 1998; 91: 1373–1381.
43. Hamilton-Dutoit S, Pallesen G, Franzmann M, et al. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol 1991; 138: 149–163.
44. Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 2003; 4: 110–119.
45. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 3406–3412.
46. Clifford G, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425–432.
47. Aljurf M, Owaidah T, Ezzat A, et al. Antigen – and/or immune-driven lymphoproliferative disorders. Ann Oncol 2003; 14: 1595–1606.
48. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102: 996–999.
49. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin‘s lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23: 468–473.
50. Ferri C, Monti M, La Civita L, et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993; 82: 3701–3704.
51. Charles E, Dustin L. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009; 76: 818–824.
52. Saadoun D, Landau D, Calabrese L, et al. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 2007; 46: 1234–1242.
53. Wotherspoon A, Ortiz-Hidalgo C, Falzon M, et al. Helicobacter pylori – associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175–1176.
54. Bende R, van Maldegem F, van Noesel C. Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas. Haematologica 2009; 94: 1109–1123.
55. Garbe C, Stein H, Dienemann D, et al. Borrelia burgdorferi – associated cutaneous B-cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol 1991; 24: 584–590.
56. Aarts W, Willemze R, Bende R, et al. VH gene analysis of primary cutaneous B-cell lymphomas: evidence for ongoing somatic hypermutation and isotype switching. Blood 1998; 92: 3857–3864.
57. Zhang G, Winter J, Variakojis D, et al. Lack of an association between Chlamydia psittaci and ocular adnexal lymphoma. Leuk Lymphoma 2007; 48: 577–583.
58. Aigelsreiter A, Leitner E, Deutsch A, et al. Chlamydia psittaci in MALT lymphomas of ocular adnexals: the Austrian experience. Leuk Res 2008; 32: 1292–1294.
59. Peek RJ. Intestinal malignancy and Campylobacter jejuni. Gastroenterology 2004; 127: 1266–1267; discussion 1267–1268.
60. Caligaris-Cappio F. Autoimmune disorders and lymphoma. Ann Oncol 2008; 19(Suppl 4): iv31–34.
61. Rodenburg R, Raats J, Pruijn G, et al. Cell death: a trigger of autoimmunity? Bioessays 2000; 22: 627–636.
62. Johnson T, Rassenti L, Kipps T. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997; 158: 235–246.
63. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 2007; 109: 259–270.
64. Kostareli E, Janus A, Gounari M, et al. Chronic Lymphocytic Leukemia with Stereotyped IGHV4-59/IGKV3-20 B Cell Receptors: Another Manifestation of Hepatitis C Virus‑Associated B Cell Lymphoproliferation? Blood ASH Annual Meeting Abstracts) 2009; 114: Abstract 2331.
65. Landgren O, Rapkin J, Caporaso N, et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood 2007; 109: 2198–2201.
66. Bende R, Aarts W, Riedl R, et al. Among B cell non-Hodgkin‘s lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 2005; 201: 1229–1241.
67. Quartuccio L, De Re V, Fabris M, et al. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. Haematologica 2006; 91: 691–694.
68. Kim H, Berek C. B-cells in rheumatoid arthritis. Arthritis Res 2000; 2: 126–131.
69. Gottenberg J, Busson M, Cohen-Solal J, et al. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjőgren‘s syndrome. Ann Rheum Dis 2005; 64: 1050–1055.
70. Hussell T, Isaacson P, Crabtree J, et al. Helicobacter pylori – specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996; 178: 122–127.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Tvarůžková Z, Pavlová Š, Doubek M, Mayer J, Pospíšilová Š. Lymphoproliferative disease in patients with autoimmune and inflammatory diseases: significance of antigenic stimulation and inflammatory processes
- Šedý J. Neurogenic pulmonary oedema
- Sobotka R, Hanuš T, Zemanová M. Principal value of surgical therapy in the renal cell cancer, chances of the biological treatment
- Filip S, Slováček L, Švecová D, Milka D, Kopecký J, Priester P, Petera J, Svoboda V. Outpatient clinic of palliative care in oncology